ISSN:
1573-0646
Keywords:
thioTEPA
;
alkylating agents
;
sarcomas
;
chemotherapy
Source:
Springer Online Journal Archives 1860-2000
Topics:
Chemistry and Pharmacology
,
Medicine
Notes:
Summary A Phase II study of thioTEPA was performed by the Children's Cancer Group. ThioTEPA was administered intravenously every three weeks, at a dose of 65 mg/m2. Pediatric patients with recurrent sarcomas were targeted, but patients with other tumor diagnoses were also eligible. Toxicity was primarily hematopoietic, with thrombocytopenia being predominant. ThioTEPA did not demonstrate significant activity in the target tumor groups evaluated.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF00873141
Permalink